Dosing and administration for M-M-R®II

Dosing and administration for M-M-R®II

M-M-R®II vaccine schedule

M-M-R®II offers health care providers like you a dosing regimen to help protect infants and children against measles, mumps, and rubella.

The First Dose of M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Should Be Given at 12-15 Months of Age

1st Dosea
12—15 months of age

The Second Dose of M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) Should Be Given at 4-6 Years of Age

2nd Doseb
4—6 years of age

FDA-approved for 40 years and counting with over 265 million doses distributed in the US

aChildren who received an initial dose of MMR vaccine prior to their first birthday should receive additional doses of vaccine at 12–15 months of age and at 4–6 years of age to complete the vaccination series.
bSecond dose may be administered prior to 4 years of age, provided that there is a minimum interval of one month between the doses of MMRV vaccine, live.

Administration

Each 0.5 mL dose of the M-M-R®II vaccine is administered subcutaneously into the outer part of the upper arm or into the anterolateral area of the thigh.


M-M-R®II: Part of the MMRV Family

While M-M-R®II can be used alone in a vaccine series, it can also be used along with other vaccines in the MMRV Family to help protect your pediatric patients with one less injection.1


Learn More About Stocking M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) in Your Professional Practice

Actual size not shown

Looking to stock M-M-R®II vaccine in your practice?

Simply register or log in to your account to get started.


CDC ACIP Recommendations for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

CDC’s ACIP Recommendations

Find out about the ACIP recommendations for MMR vaccinations in pediatric patients.2

Find Out About the Flexible Storage Options and Ease of Handling M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

Storage and Handling

Find out about the flexible storage options and ease of handling M-M-R®II can bring to your practice.

ref1

Reference

  1. Marin M, Broder KR, Temte JL, et al. Centers for Disease Control and Prevention. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(3):1-12.
ref2

Reference

  1. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2022. Updated February 17, 2022. Accessed March 14, 2022. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf

Indications and Usage for M-M-R®II

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

DOSAGE AND ADMINISTRATION

  • FOR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live) is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during clinical trials or reported during post-approval use of M-M-R®II or its components: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

DOSAGE AND ADMINISTRATION

  • FOR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

M-M-R®II is contraindicated in certain individuals, including those with: a history of

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

Thank you for visiting.


US-MMR-00141 05/22